Literature DB >> 10475959

The capsule of bacillus anthracis, a review

.   

Abstract

The capsule of Bacillus anthracis, composed of poly-D-glutamic acid, serves as one of the principal virulence factors during anthrax infection. By virtue of its negative charge, the capsule is purported to inhibit host defence through inhibition of phagocytosis of the vegetative cells by macrophages. In conjunction with lethal toxin and oedema toxin, whose target cells include macrophages and neutrophils, respectively, the capsule allows virulent anthrax bacilli to grow virtually unimpeded in the infected host. Spores germinating in the presence of serum and elevated CO2 release capsule through openings on the spore surface in the form of blebs which may coalesce before sloughing of the exosporium and outgrowth of the fully encapsulated vegetative cell. It has not been established that spore encapsulation plays a role in the early events of anthrax infection. The capsule appears exterior to the S-layer of the vegetative cell and does not require the S-layer for its attachment to the cell surface. The three membrane-associated enzymes required for synthesis of the capsule are encoded by the 60-MDa pX02 plasmid. The cistrons are arranged in the order capB, capC and capA and encode for proteins of 44, 16 and 46 kDa, respectively. The synthesis of capsule and toxin is, in part, under bicarbonate regulation by interaction of transacting proteins of the atxA gene on the 100-MDa pX01 toxin-encoding plasmid and the acpA gene on the pX02 plasmid. Therefore, capsule synthesis is enhanced in the presence of the atxA gene on the pX01 plasmid. An additional protein (with a predicted size of 51 kDa) is encoded by the dep gene located downstream from the cap region and appears to be a depolymerase that catalyses the hydrolysis of poly-D-glutamic acid into lower molecular weight polyglutamates. Although the biological function of the Dep protein is unknown, it has been proposed that the low molecular weight polyglutamates produced by the action of the enzyme may act to inhibit host defence mechanisms.

Entities:  

Year:  1999        PMID: 10475959     DOI: 10.1046/j.1365-2672.1999.00881.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  39 in total

1.  Evidence for the horizontal transfer of an unusual capsular polysaccharide biosynthesis locus in marine bacteria.

Authors:  Alina Nakhamchik; Caroline Wilde; Henry Chong; Dean A Rowe-Magnus
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

2.  Pathogenomic sequence analysis of Bacillus cereus and Bacillus thuringiensis isolates closely related to Bacillus anthracis.

Authors:  Cliff S Han; Gary Xie; Jean F Challacombe; Michael R Altherr; Smriti S Bhotika; Nancy Brown; David Bruce; Connie S Campbell; Mary L Campbell; Jin Chen; Olga Chertkov; Cathy Cleland; Mira Dimitrijevic; Norman A Doggett; John J Fawcett; Tijana Glavina; Lynne A Goodwin; Lance D Green; Karen K Hill; Penny Hitchcock; Paul J Jackson; Paul Keim; Avinash Ramesh Kewalramani; Jon Longmire; Susan Lucas; Stephanie Malfatti; Kim McMurry; Linda J Meincke; Monica Misra; Bernice L Moseman; Mark Mundt; A Christine Munk; Richard T Okinaka; B Parson-Quintana; Lee Philip Reilly; Paul Richardson; Donna L Robinson; Eddy Rubin; Elizabeth Saunders; Roxanne Tapia; Judith G Tesmer; Nina Thayer; Linda S Thompson; Hope Tice; Lawrence O Ticknor; Patti L Wills; Thomas S Brettin; Paul Gilna
Journal:  J Bacteriol       Date:  2006-05       Impact factor: 3.490

3.  Bacillus anthracis sortase A (SrtA) anchors LPXTG motif-containing surface proteins to the cell wall envelope.

Authors:  Andrew H Gaspar; Luciano A Marraffini; Elizabeth M Glass; Kristin L Debord; Hung Ton-That; Olaf Schneewind
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

4.  Sepsis and pathophysiology of anthrax in a nonhuman primate model.

Authors:  Deborah J Stearns-Kurosawa; Florea Lupu; Fletcher B Taylor; Gary Kinasewitz; Shinichiro Kurosawa
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

5.  Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax.

Authors:  Itai Glinert; Elad Bar-David; Assa Sittner; Shay Weiss; Josef Schlomovitz; Amir Ben-Shmuel; Adva Mechaly; Zeev Altboum; David Kobiler; Haim Levy
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

6.  Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo.

Authors:  Jason E Comer; Ashok K Chopra; Johnny W Peterson; Rolf König
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

7.  Comprehensive Laboratory Evaluation of a Highly Specific Lateral Flow Assay for the Presumptive Identification of Bacillus anthracis Spores in Suspicious White Powders and Environmental Samples.

Authors:  Jason G Ramage; Kristin W Prentice; Lindsay DePalma; Kodumudi S Venkateswaran; Sruti Chivukula; Carol Chapman; Melissa Bell; Shomik Datta; Ajay Singh; Alex Hoffmaster; Jawad Sarwar; Nishanth Parameswaran; Mrinmayi Joshi; Nagarajan Thirunavkkarasu; Viswanathan Krishnan; Stephen Morse; Julie R Avila; Shashi Sharma; Peter L Estacio; Larry Stanker; David R Hodge; Segaran P Pillai
Journal:  Health Secur       Date:  2016 Sep-Oct

8.  Transcriptional profiling of Bacillus anthracis during infection of host macrophages.

Authors:  Nicholas H Bergman; Erica C Anderson; Ellen E Swenson; Brian K Janes; Nathan Fisher; Matthew M Niemeyer; Amy D Miyoshi; Philip C Hanna
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

9.  Discriminating virulence mechanisms among Bacillus anthracis strains by using a murine subcutaneous infection model.

Authors:  Hitendra S Chand; Melissa Drysdale; Julie Lovchik; Theresa M Koehler; Mary F Lipscomb; C Rick Lyons
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

10.  A two-component direct fluorescent-antibody assay for rapid identification of Bacillus anthracis.

Authors:  Barun K De; Sandra L Bragg; Gary N Sanden; Kathy E Wilson; Lois A Diem; Chung K Marston; Alex R Hoffmaster; Gwen A Barnett; Robbin S Weyant; Teresa G Abshire; John W Ezzell; Tanja Popovic
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.